1. Home
  2. RCUS vs MGNI Comparison

RCUS vs MGNI Comparison

Compare RCUS & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

N/A

Current Price

$25.23

Market Cap

3.2B

Sector

Health Care

ML Signal

N/A

Logo Magnite Inc.

MGNI

Magnite Inc.

N/A

Current Price

$25.44

Market Cap

3.5B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
RCUS
MGNI
Founded
2015
2007
Country
United States
United States
Employees
N/A
971
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.5B
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
RCUS
MGNI
Price
$25.23
$25.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
15
Target Price
★ $39.91
$28.80
AVG Volume (30 Days)
1.5M
★ 2.2M
Earning Date
10-27-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 493.75
EPS
N/A
★ 0.16
Revenue
★ $247,000,000.00
$156,414,000.00
Revenue This Year
N/A
$6.65
Revenue Next Year
N/A
$9.83
P/E Ratio
★ N/A
$161.19
Revenue Growth
N/A
★ 25.45
52 Week Low
$13.21
$10.82
52 Week High
$31.74
$26.84

Technical Indicators

Market Signals
Indicator
RCUS
MGNI
Relative Strength Index (RSI) 45.70 58.91
Support Level $25.94 $11.61
Resistance Level $26.43 $25.53
Average True Range (ATR) 1.07 0.97
MACD 0.10 0.01
Stochastic Oscillator 58.61 61.73

Price Performance

Historical Comparison
RCUS
MGNI

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

About MGNI Magnite Inc.

Magnite is a supply-side advertising platform that provides technology and yield management solutions to content publishers, enabling them to monetize their digital advertising inventory. Magnite receives a percentage of all advertising inventory that it sells. 43% of Magnite's revenue is derived from connected television, or CTV, streaming platforms, 40% from mobile applications, and the remainder from general websites. Beyond the typical monetization responsibilities inherent to an SSP, Magnite also provides upstream advertising servers to CTV publishers, allowing them to have granular control over direct-sold, programmatic guaranteed, and open-auction logic. Magnite competes with other independent SSPs, supply path optimization solutions, and closed ecosystems like Meta.

Share on Social Networks: